Jan 22, 2026
Which systemic therapy intensification strategies (ADT+ARPI vs ADT+docetaxel) show survival benefit in newly diagnosed high‑grade, low‑PSA metastatic prostate cancer?
Both approaches—adding an androgen‑receptor pathway inhibitor (ARPI) to androgen‑deprivation therapy (ADT) and adding docetaxel to ADT—have randomized evidence of overall‑survival benefit versus ADT a...